Detection of antibodies to squalene III. Naturally occurring antibodies to squalene in humans and mice

Journal of Immunological Methods

Volumn 286, Issue 1-2, 2004, Pages 47-67

  Matyas, Gary R ^a   Rao, Mangala ^a   Pittman, Phillip R ^b   Burge, Robert ^a   Robbins, Iris E ^a,c   Wassef, Nabila M ^a,d   Thivierge, Brandie ^a   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

2,2 azino di (3 erthylbenzthiazoline 6 sulfonate); ABTS; Anthrax vaccine absorbed (licensed U.S. anthrax vaccine); Anthrax vaccine adsorbed; Antibody detection; AVA; Bovine serum albumin; BSA; Enzyme linked immunosorbent assay; FBS; Squalene

Indexed keywords

ANTHRAX VACCINE; BUFFER; CASEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHATE; SQUALENE DERIVATIVE;

ADULT; AGE DETERMINATION; AGED; ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOASSAY; MATERIAL COATING; NONHUMAN; PLASMA; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SERUM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; ANTHRAX VACCINES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MIDDLE AGED; SEX FACTORS; SQUALENE;

ANIMALIA; ANTHRAX; BOVINAE; MURINAE;

EID: 1842861810     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2003.11.002     Document Type: Article

References (52)

1. Aggarwal B.B., Moffat B., Harkins R.N. Human lymphotoxin: production by a lymphoblastoid cell line, purification, and initial characterization. J. Biol. Chem. 259:1984;686.
2. Alving C.R. Natural antibodies against phospholipids and liposomes in humans. Biochem. Soc. Trans. 12:1984;342.
3. Alving C.R., Grabenstein J.D. Letters to the editor. Exp. Mol. Pathol. 68:2000;196.
4. Alving C.R., Wassef N.M. Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Immunol. Today. 20:1999;362.
5. Alving C.R., Swartz G.M. Jr., Wassef N.M. Naturally occurring autoantibodies to cholesterol in humans. Biochem. Soc. Trans. 17:1989;637.
6. Asa P.B., Cao Y., Garry R.F. Antibodies to squalene in gulf war syndrome. Exp. Mol. Pathol. 68:2000;55.
7. Asa P.B., Wilson R.B., Garry R.F. Antibodies to squalene in recipients of anthrax vaccine. Exp. Mol. Pathol. 73:2002;19.
8. Beaumont V., Gioud-Paquet M., Kahn M.F., Beaumont J.L. Antiestrogen antibodies, oral contraception and systemic lupus erythematosus. Clin. Physiol. Biochem. 7:1989;263.
9. Brochu M., Veilleux R., Lorrain A., Belanger A. Monoclonal antibodies for use with 125-Iodine-labeled radioligands in progesterone radioimmunoassay. J. Steroid Biochem. 21:1984;405.
10. Bucala R., Lahita R.G., Fishman J., Cerami J. Anti-oestrogen antibodies in users of oral contrcptivs and in patients with systemic lupus erythamatosus. Clin. Exp.Immunol. 67:1987;167.
11. Counihan K.A., Vertosick F.T., Kelly R.H. Anti-estrogen antibodies in systemic lupus erythematosus: a quantitative evaluation of serum levels. Immunol. Invest. 20:1991;317.
12. Cunningham C.K., Wara D.W., Kang M., Fenton T., Hawkins E., McNamara J., Mofenson L., Duliege A.M., Francis D., McFarland E.J., Borkowsky W. Pediatric AIDS Clinical Trials Group 230 Collaborators Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin. Infect. Dis. 32:2001;801.
13. Dörsam H., Rohrabach P., Kürschner T., Kipriyanov S., Renner S., Braunagel M., Welschof M., Little M. Antibodies to steroids from a small human naive IgM library. FEBS Lett. 414:1997;7.
14. Drulak M.W., Malinoski F.J., Fuller S.A., Stewart S.S., Hoskin S., Duliege A.-M., Sekulovich R., Burke R., Winston S. Vaccination of serpositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin. Viral Immunol. 13:2000;49.
15. Fahey J.L., Buell D.N., Sox H.C. Proliferation and differentiation of lymphoid cells: studies with human lymphoid cell lines and immunoglobulin synthesis. Ann. N.Y. Acad. Sci. 190:1971;221.
16. Fantl V.E., Wang D.Y. Simultaneous production of monoclonal antibodies to dehydroepiandresterone, oestradiol, progesterone and testosterone. J. Endocrinol. 100:1984;367.
17. Franek M. Structural aspects of steroid-antibody specificity. J. Steroid Biochem. 28:1987;95.
18. Fulco C.E., Liverman C.T., Sox H.C. Gulf War and Health: Depleted Uranium, Pyridostigmine Bromide, Sarin, Vaccines. 1:2000;307 National Academy Press, Washington, DC.
19. Gasparini R., Pozzi T., Montomoli E., Fragapane E., Senatore F., Minutello M., Podda A. Increased immunogenicity of the MF-59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17:2001;135.
20. Gigliotti F., Smith L., Insel R.A. Reproducible production of protective human monoclonal antibodies by fusion of peripheral blood lymphocytes with a mouse myeloma cell line. J. Infect. Dis. 149:1984;43.
21. Granner D.K. Hormones of the adrenal cortex. Murray R.K., Granner D.K., Mayes P.A., Rodwell V.W. Harper's Biochemistry. 24th ed. 1996;547 Appleton & Lang, Stamsord.
22. Grover P.K., Odell W.D. Specificity of antisera to sex steroids I - the effect of substitution and sterochemistry. J. Steroid Biochem. 28:1977;121.
23. Harro C.D., Pang Y.-Y.S., Roden R.B.S., Hildesheim A., Wang Z., Reynolds M.J., Mast T.C., Robinson R., Murphy B.R., Karron R.A., Dilner J., Schiller J.T., Lowy D.R. Safety and immunogenicity trial in adult volunteers of human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:2001;284.
24. Heineman T.C., Clements-Mann M.L., Poland G.A., Jacobson R.M., Izu A.E., Sakamoto D., Eiden J., Van Nest G.A., Hsu H.H. A randomized controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine. 17:1999;2769.
25. Irie, R.F., 1995. Human B-lymphoblastoid cell line secreting anti-ganglioside antibody. U.S. patent, serial no. 5, 419, 921.
26. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV infected human volunteers. J. Infect. Dis. 170:1994;1288.
27. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., Krzych U., Delchambre M., Voss G., Dowler M.G., Palensky J., Wittes J., Cohen J., Ballou W.R. Efficacy of recombinant circumsporozite protein vaccine regimens against experimental plasmodium falciparum malaria. J. Infect. Dis. 183:2001;640.
28. Kuwahara A., Kamada M., Irahara M., Naka O., Yamashita T., Aono T. Autoantibody against testosterone in a woman with hypergonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 83:1998;14.
29. Koivisto P.V.I., Miettinen T.A. Increased amount of cholesterol precursors in lipoprotein after ileal exclusion. Lipids. 23:1988;993.
30. Larrick, J.W., Raubitschek, A.R., Truitt, K.E., 1986. Human lymphoblastold cell line and hybridoma derived thereform. U.S. patent, serial no. 4, 624, 921.
31. Mais D.E., Hayes J.S., Heap R.B., Wang M.-W. Specific interactions of progestins and anti-progestins with progesterone antibodies, plasma binding proteins and the human recombinant receptor. J. Steroid Biochem. Mol. Biol. 54:1995;63.
32. Matyas G.R., Wassef N.M., Rao M., Alving C.R. Induction and detection of antibodies to squalene. J. Immunol. Methods. 245:2000;1.
33. Matyas G.R., Rao M., Alving C.R. Induction and detection of antibodies to squalene II. Optimization of the assay for murine antibodies. J. Immunol. Methods. 267:2002;119.
34. Mayes P.A. Cholesterol synthesis, transport, and excretion. Murray R.K., Granner D.K., Mayes P.A., Rodwell V.W. Harper's Biochemistry. 24th ed. 1996;27 Appleton & Lang, Stamsord.
35. McFarland E.J., Borkowsky W., Fenton T., Wara D., McNamara J., Samson P., Kang M., Mofenson L., Cunningham C., Duliege A.-M., Sinangil F., Spector S.A., Jimenez E., Bryson Y., Burchett S., Frenkel L.M., Yogev R., Giglitotti F., Luzuriaga K., Livingston R.A. the AIDS clinical trials group 230 collaborators Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis. 184:2001;1331.
36. Metcalf, J., 2000. http://www.house.gov/metcalf/report.htm, appendix 25.
37. Miettinen T.A. Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoprotein. J. Lipid Res. 23:1982;466.
38. Mitchell D.K., Holmes S.J., Burke R.L., Duliege A.M., Adler S.P. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. 21:2002;133.
39. Moinuddin, Ali A. Binding of naturally occurring anti-DNA antibodies to estradiol. Biochem. Mol. Biol. Int. 45:1998;511.
40. Newhook R., Caldwell I. Exposure to styrene in the general Canadian population. IARC Sci. Publ. 127:1993;27.
41. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., Zambon M.C. Safety and antigenicity of non-adjuvanted and MF-59-adjuvanted influenza A/Duck/Singpore 97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet. 357:2001;1937.
42. Ott G., Radhakrishnan R., Fant J., Hora M. The adjuvant MF59: a 10 year perspective. O'Hagan D.T. Vaccine adjuvants: preparation Methods and Research Protocols. Meth. Mol. Med. vol. 42:2000;211 Humana Press, Totowa.
43. Pinto M., Rimon A. Anti-steroid factor/s in normal and pathological human sera. Vox Sang. 18:1970;155.
44. Pittman P.R., Gibbs P.H., Cannon T.L., Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine. 20:2002;972.
45. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 19:2001;2673.
46. Relas H., Gylling H., Miettinen T.A. Fate of intravenously administered squalene and plant sterols in human subjects. J. Lipid Res. 42:2001;988.
47. Rickman L.S., Gordon D.M., Wistar R. Jr., Krzych U., Gross M., Hollingdale M.R., Egan J.E., Chulay J.D., Hoffman S.L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalene in malaria circumsporozite protein vaccine. Lancet. 337:1991;998.
48. Spanggord R.J., Wu B., Sun M., Lim P., Elis W.Y. Development and application of an analytical method for the determination of squalene in formulations of anthrax vaccine adsorbed. J. Pharm. Biomed. Anal. 29:2002;183.
49. Stewart M.E. Sebaceous gland lipids. Semin. Dermatol. 11:1992;100.
50. Stoute J.A., Slaoui M., Heppner G., Momin P., Kester K.E., Desmons P., Wellde G.T., Garcon N., Krzych U., Marchand M., Ballou W.R., Cohen J.D. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria. New Engl. J. Med. 336:1997;86.
51. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., Glenn G., Ockenhouse C.F., Garcon N., Schwenk R., Lanar D.E., Sun P., Momin P., Wirtz R.A., Golenda C., Slaoui M., Wortmann G., Holland C., Dowler M., Cohen J., Ballou W.R. Long-term efficacy and immune responses following immunization with the RTSS malaria vaccine. J. Infect. Dis. 178:1998;1139.
52. Teng N.N.H., Kaplan H.S., Herbert J.M., Morre C., Douglas H., Wunderlich A., Braude A.I. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Natl. Acad. Sci. U. S. A. 82:1985;1790.